CD70 and neoplasm: Amidst repeated CD70+ tumor challenges, ADP-520 TRuC T cells showed slower kinetics and reduced co-expression of exhaustion markers, such as PD-1, the receptor for PD-L1, whose intratumoral expression was linked to poor clinical efficacy of gavo-cel TRuC T-cell therapy (12).